Intellia Therapeutics, Inc. (NASDAQ:NTLA) just released its latest quarterly results and things are looking bullish. Revenues of US$17m beat estimates by a substantial 39% margin. Unfortunately, ...

Repligen Corp. research and ratings by Barron's. View RGEN revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.

Discover Q1 2025 earnings insights from Intellia Therapeutics (NTLA): Phase 3 progress, RMAT milestones, financial outlook, and competitive gene editing edge.

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos” or the "Company”), today announced its 2025 first quarter business ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of ...

Perrigo PRGO reported adjusted earnings of 60 cents per share in the first quarter of 2025, beating the Zacks Consensus ...

Jazz Pharmaceuticals JAZZ reported first-quarter 2025 adjusted earnings of $1.68 per share, which significantly missed the ...

Analysts expect Intellia Therapeutics to report an earnings per share (EPS) of $-1.27. Anticipation surrounds Intellia ...

Solomon Partners Securities, LLC acted as financial advisor to Lantheus in this transaction, while Foley Hoag LLP and Ropes & Gray LLP acted as legal advisors, and Ernst & Young LLP acted as financial ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...